Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Major Corporate Updates

South San Francisco, Calif. – March 9, 2026 – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on therapies for neurological disorders with significant unmet medical need, has released its financial results for the year ended December 31, 2025, alongside several price-sensitive corporate developments that could shape the company’s future and investor outlook.

Key Corporate Highlights and Potential Share Price Catalysts

• TA-ERT Program Progress: Spruce is making substantial progress with tralesinidase alfa enzyme replacement therapy (TA-ERT), targeting Sanfilippo Syndrome Type B (MPS IIIB). Following positive Type B meetings with the FDA in February 2026, the company remains on track to submit a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026. The FDA indicated that integrated interventional study data and natural history data could serve as an “adequate and well-controlled study” for review. Importantly, the FDA acknowledged that heparan sulfate non-reducing end in cerebrospinal fluid could be a reasonable surrogate endpoint for clinical benefit, supporting a potential accelerated approval—a major regulatory milestone that could drive significant value for shareholders should approval be granted.
• Executive Appointments to Drive Commercialization: Spruce has appointed Dale Hooks as Chief Commercial Officer, bringing over three decades of biopharmaceutical marketing and commercialization expertise, signaling advanced preparations for the potential launch of TA-ERT. Additionally, in February 2026, Daven Mody, Pharm.D. (SVP, Regulatory and Quality) and Bruno Gagnon, B.Pharm., M.Sc. (SVP, Clinical Development Operations) joined the executive team, while Keli Walbert, a proven pharmaceutical commercial leader, was appointed to the Board of Directors in December 2025. These leadership additions bolster the company’s regulatory and commercial capabilities as it nears a pivotal inflection point.
• Growth Capital Secured: In January 2026, Spruce entered a loan facility with Avenue Capital Group for up to \$50 million in growth capital. An initial \$15 million tranche was fully funded, with three further tranches totaling \$35 million available subject to certain milestones. This financing provides a critical cash runway to support both TA-ERT’s continued development and a potential commercial launch.
• Promising Clinical Data Presented: At the 22nd Annual WORLDSymposium in February, long-term TA-ERT data was presented, showing rapid and durable reduction in heparan sulfate and preserved cognitive and non-cognitive outcomes in MPS IIIB patients compared to natural history controls. Strikingly, case studies of two siblings with MPS IIIB showed the treated sibling outperformed the untreated sibling on cognitive, language, and motor function—reinforcing TA-ERT’s potential as the first disease-modifying therapy for this devastating pediatric disease.
• Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorized: In February 2026, the PRV program was extended through September 2029. TA-ERT, already holding Rare Pediatric Disease Designation, would be eligible for a valuable PRV upon FDA approval—potentially monetizable for tens of millions of dollars and a significant non-dilutive asset for the company.

Full Year 2025 Financial Results

• Cash Position: Cash and cash equivalents as of December 31, 2025, totaled \$48.9 million, excluding the \$15 million received in January 2026. The company expects this cash to fund its operating plan into early 2027, providing a runway beyond the anticipated TA-ERT BLA submission.
• R&D Expenses: Research and development expenses fell sharply to \$19.5 million from \$46.4 million in 2024, primarily due to the cessation of tildacerfont development for congenital adrenal hyperplasia (CAH). R&D now focuses on TA-ERT and the acquisition of SPR202, an anti-corticotropin releasing hormone mAb for CAH.
• G&A Expenses: General and administrative expenses rose to \$17.0 million from \$14.6 million, driven mainly by increased professional service fees, offset by lower stock-based compensation.
• Total Operating Expenses: Total operating expenses decreased to \$36.5 million from \$61.1 million in 2024.
• Net Loss: Net loss for 2025 improved to \$39.0 million from \$53.0 million in 2024, reflecting the streamlined focus and expense reductions.
• Balance Sheet: Total assets at year-end were \$53.0 million with total liabilities of \$10.5 million. Stockholders’ equity increased to \$42.5 million from \$28.8 million year-over-year.

What Investors Need to Know

• TA-ERT is on track for a pivotal BLA submission in Q4 2026 and could be the first FDA-approved, disease-modifying therapy for MPS IIIB—a significant, potentially transformative catalyst for the company and the share price.
• Recent positive FDA guidance and the potential for accelerated approval de-risk the regulatory path and could bring forward revenues.
• Strong cash reserves and new growth capital ensure the company is well funded through critical upcoming milestones.
• Eligibility for a Priority Review Voucher upon approval represents a potential windfall and non-dilutive source of funding.
• Experienced commercial and regulatory leadership positions Spruce for a successful product launch if TA-ERT is approved.

Conclusion

Spruce Biosciences has made significant regulatory, clinical, and financial progress in 2025 and early 2026, with multiple price-sensitive catalysts ahead. The approaching BLA submission, recent positive FDA feedback, strong long-term clinical data, the reauthorization of the PRV program, and robust management appointments all point to a pivotal period for the company. Investors should closely monitor developments, as successful regulatory milestones and a potential TA-ERT approval could materially impact Spruce’s valuation and share price.

Disclaimer: This article contains forward-looking statements based on current interpretations of the company’s filings and press release. Actual results may differ materially due to risks, uncertainties, and other factors. Investors should review the company’s SEC filings for a fuller understanding of risk factors before making investment decisions.

View SPRUCE BIOSCIENCES, INC. Historical chart here